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Abstract
Introduction: N-terminal pro-B-type natriuretic peptide (NT-proBNP) has emerged 
as an important biomarker for developing the diagnosis and prognosis of cardiovascular 
diseases, as several studies have shown that serum levels of NT-proBNP elevate in acute 
coronary syndrome (ACS) and coronary artery disease (CAD). We performed this study 
to find any possible correlation between serum levels of NT-proBNP and Gensini score in 
patients diagnosed with ACS.
Methods: In a cross-sectional study, 100 consecutive patients with ACS who were 
candidates of angiography were recruited and their serum levels of NT-proBNP, Gensini 
scores, lipid profiles and troponin I levels were measured.
Results: Sixty six male and 34 female patients with a mean age of 57.5 years, including 
44 with unstable angina, 33 with ST-elevation myocardial infarction, and 23 with non-
ST-elevation myocardial infarction were enrolled. The mean serum NT-proBNP level and 
the Gensini score were 1987.16 pg/mL (17.9-8841) and 31.09 (6-92.5), respectively. 
The serum NT-proBNP levels and Gensini scores were significantly correlated with a 
Spearman correlation coefficient of 0.953 (P < 0.001). Serum levels of NT-proBNP were 
not different in patients with single-vessel disease, 2-vessel disease and 3-vessel disease 
(P = 0.257). NT-Pro-BNP levels were also correlated positively with troponin I levels 
(correlation coefficient = 0.779) and negatively with left ventricular ejection fraction 
(correlation coefficient = -0.55). Smoker patients had higher NT-proBNP levels (P = 
0.047). Neither Gensini scores nor NT-Pro-BNP levels had significant correlation with 
lipid profile or blood sugar.
Conclusions: NT-proBNP is directly correlated with Gensini score in patients with ACS 
and might be used as an important marker for risk stratification in those patients.
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During recent years, new cardiac biomarkers have been ex-
plored as useful tools for diagnosis and risk stratification in 
patients with cardiovascular diseases including acute coro-
nary syndrome (ACS) and coronary artery disease (CAD). 
One of the biomarkers that have been studied and shown 
promise in clinical practice is N-terminal pro-B-type na-
triuretic peptide (NT-proBNP). BNP is synthesized as a 
108-aminoacid-long prohormone termed proBNP and se-
creted mainly from cardiac atrial and ventricular myocardi-
um in response to increases in wall stress or inflammation 
[1-4]. After secretion, this propeptide is divided into its bi-
ologically active BNP and the NT-proBNP.
Several studies have shown that serum levels of NT-proB-
NP elevate in a variety of functional and structural cardiac 
abnormalities, especially ACS and CAD [4-11]; therefore, 
NT-proBNP has emerged as an important biomarker for 
developing diagnosis and prognosis for cardiovascular dis-
eases [12-14]. Some studies have reported the beneficial 
effects of NT-proBNP as a prognostic marker for predicting 
CAD severity based on angiographic findings [10, 15-18] as 
well as infarct size and myocardial function after myocardial 
infarction (MI) [11, 19, 20]. Meanwhile, other studies have 
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suggested the predictive role of this peptide for assessing 
long-term mortality of patients with CAD [21-23]. Pro-
viding the establishment of NT-proBNP as an approved 
biomarker for risk stratification and predicting CAD sever-
ity in patients with ACS, measurement of this peptide as a 
non-invasive rapid and simple method can replace other 
invasive and costly procedures.
Based on these evidences, we performed this study to eval-
uate whether serum level of NT-proBNP is an appropriate 
predictor of CAD severity in patients with ACS. To achieve 
this goal, we tried to find any possible correlation between 
serum levels of NT-proBNP and Gensini scores in patients 
diagnosed with ACS. 
METHODS
In a cross-sectional study, 100 consecutive patients, ad-
mitted in CCU of Shahid Modarres Hospital (a university 
hospital affiliated to Shahid Beheshti University of Medical 
Sciences in Tehran, Iran) in 2012 with diagnosis of ACS, 
were recruited. They included patients with unstable angi-
na (UA), ST-elevation MI (STEMI), and non-ST-elevation 
MI (NSTEMI). Patients with ACS who were candidates of 
angiography were offered to participate in the study and in 
case of consent, a questionnaire was filled for each of them 
comprising their basic medical and demographic informa-
tion. Twenty four hours after patients’ last episode of chest 
pain, 5 mL of their venous blood was taken and their serum 
levels of NT-proBNP, troponin-I and creatinine, low-den-
sity lipoprotein (LDL), high-density lipoprotein (HDL), 
cholesterol, triglyceride (TG) and blood sugar were mea-
sured. Levels of NT-proBNP were measured by Enhanced 
Chemi luminescence (ECL) using Pro-BNP kit (Roche, 
Germany).
Patients underwent angiography by expert attending phy-
sicians. According to the angiograms, patients were divid-
ed into patients with single-vessel disease (SVD), 2-vessel 
disease (2VD), 3-vessel disease (3VD) and patients with 
isolated or concomitant left main artery (LM) involvement. 
The Gensini score was calculated for each patient from the 
coronary arteriogram by assigning a severity score to each 
coronary stenosis, according to the degree of luminal nar-
rowing and its geographic importance. Reduction in the lu-
men diameter, as well as the roentgenographic appearance 
of concentric lesions and eccentric plaques were evaluated 
(reductions of 25%, 50%, 75%, 90%, 99%, and complete oc-
clusion were given Gensini scores of 1, 2, 4, 8, 16, and 32, 
respectively). Each principal vascular segment was assigned 
a multiplier in accordance with the functional significance 
of the myocardial area supplied by that segment: the left 
main coronary artery × 5; the proximal segment of left ante-
rior descending coronary artery (LAD) × 2.5; the proximal 
segment of the circumflex artery × 2.5; the mid-segment of 
the LAD × 1.5; the right coronary artery, the distal segment 
of the LAD, the posterolateral artery and the obtuse mar-
ginal artery × 1; and others × 0.5 [24, 25]. Angiograms were 
read by two independent readers blinded to patients’ data 
and then averaged.
The exclusion criteria were creatinine> 1.5 mg/dL, fever, 
body mass index > 30, left ventricular ejection fraction 
(EF) < 40%, age > 75 years, and sever hepatic or pulmonary 
diseases. We used SPSS software version 15 for data anal-
ysis. Quantitative variables are presented as mean. T-test 
and ANOVA were used for comparing two or multiple vari-
ables. To find any possible correlation of Gensini scores and 
serum levels of NT-proBNP with other variables, Pearson’s 
and Spearman’s correlation tests were used. A P value of < 
0.05 was considered as statistically significant.
The study protocol was approved by the Ethics Committee 
of Shahid Beheshti University of Medical Sciences. A writ-
ten informed consent was obtained from each participant 
according to the Declaration of Helsinki.
RESULTS
Among 100 patients enrolled in the study, 66 were male and 
34 were female. The mean age of the participants was 57.5 ± 
19.6 years; 44 had UA, 33 had STEMI and 23 had NSTEMI. 
Regarding their EF, 46% had EF of 60% or higher, 17% had 
EF of 55-60%, 36% had EF of 50-55% and one patient had 
an EF of 45-50%. Fifty four patients were smokers. Labora-
tory and clinical results of the patients are shown in Table 1.
The mean serum levels of troponin I and NT-proBNP and 
the mean Gensini score were 11.3 μg/L (range: < 0.05 to 
53), 1987.16 pg/mL (range: 17.9-8841), and 31.09 (range: 
6-92.5), respectively. Angiography showed that 19% of the 
patients had SVD, 48% had 2VD, 27% had 3VD and the 
other 6% had isolated or concomitant LM involvement. 
Of the patients, 79% had isolated or concomitant LAD in-
volvement and LAD was not found in the remaining 21% 
of the patients.
Table 1: Laboratory and Clinical Results of the Patients
Variable Result
Creatinine (mg/dL) 1.09 ± 0.1
Blood sugar (mg/dL) 182.7 ± 83.8
LDL (mg/dL) 115.8 ± 21.8
Triglyceride (mg/dL) 321.8 ± 76.9
Cholesterol (mg/dL) 277.2 ± 58.0
HDL (mg/dL) 44.03 ± 7.7
Systolic blood pressure (mmHg) 140.0 ± 16.2
Diastolic blood pressure(mmHg) 84.1 ± 9.3
Data in table are presented as Mean ± SD.
LDL: Low-density lipoprotein; HDL: High-density lipoprotein
We tried to find any possible correlation between the 
serum level of NT-proBNP and Gensini score in our pa-
tients. Using Spearman’s correlation test, the correlation 
coefficient was 0.953 (P < 0.001), which showed a signifi-
cant direct correlation between the two variables. The cor-
relation was significant in both genders, as the Spearman’s 
coefficients were 0.977 and 0.862 in males and females, 
respectively (P < 0.001 in both). Fig 1-3 depict the cor-
relation between serum levels of NT-proBNP and Gensini 
score in all the patients and each gender. Additionally, the 
correlation was significant in all three groups of patients 
with ACS (Table 2).
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Table 2: The Correlation between Serum Levels of NT-proBNP and Gensini Scores in Three Subgroups of Patients with ACS
Group Pearson’s correlation coefficient P value
UA 0.80 < 0.001
STEMI 0.96 < 0.001
NSTEMI 0.92 < 0.001
UA: unstable angina; STEMI: ST elevation myocardial infarction; NSTEMI: non-ST elevation myocardial infarction
Figure 1: Correlation between Serum Levels of NT-proBNP and 
Gensini Scores in Patients
Figure 2: Correlation between Serum Levels of NT-proBNP and 
Gensini Scores in Males
ANOVA showed no significant difference between serum 
levels of NT-proBNP among the four groups of patients with 
SVD, 2VD, 3VD and patients with isolated or concomitant 
LM involvement (P = 0.257). Regarding the serum levels of 
NT-proBNP, there was also no significant difference between 
patients with and without LAD involvement (P = 0.294). 
However, the difference was significant comparing patients 
with UA, STEMI and NSTEMI (P < 0.001).
In this study, patients with positive troponin I had higher 
NT-proBNP levels (P < 0.001) and the correlation coefficient 
between them was 0.779 (Fig 4). There was also a significant 
indirect correlation between serum level of NT-PRO-BNP and 
EF with a correlation coefficient of -0.55 (P = 0.001). 
Figure 3: Correlation between Serum Levels of NT-proBNP and 
Gensini Scores in Females
Figure 4: Correlation between Troponin I and NT-proBNP Levels
Besides, while there was no significant difference in Gensini 
scores of smoker and non-smoker patients (P = 0.08); smoker 
patients had higher NT-proBNP levels (P = 0.047).
There was no correlation in Gensini scores and NT-proBNP 
levels with laboratory results of the patients (Tables 3 and 4).
DISCUSSION
In this study, we recruited patients with ACS and studied 
the correlation between their serum levels of NT-proBNP 
and Gensini scores. We found that the Spearman’s coeffi-
cient of the correlation between serum levels of NT-proBNP 
and Gensini scores in our patients with ACS was 0.953 (P < 
0.001), which showed a powerful direct correlation between
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Table 3: Correlation between Gensini Score and Laboratory Results
Variable Correlation coefficient P value





HDL: High-density lipoprotein; LDL: Low-density lipoprotein
Table 4: Correlation between Serum Level of NT-proBNP and Laboratory Results
Variable Correlation coefficient P value





HDL: High-density lipoprotein; LDL: Low-density lipoprotein
the two variables. The correlation was also statistically signifi-
cant in both genders and in three subgroups of patients with 
UA, STEMI and NSTEMI. NT-proBNP was first used as an 
indicator of heart failure and stress on myocardial tissue; but 
it seems that it can also be considered as a valuable biomarker 
for predicting the severity of CAD and therefore the severity 
of myocardial ischemia.
The results of our study about the correlation between 
NT-proBNP and Gensini score are consistent with previous 
reports. Wei and colleagues reported that NT-proBNP levels 
were found to go higher with the severity of myocardial isch-
emia in patients with UA [26]. In a study on patients with 
NSTEMI, the NT-proBNP levels progressively increased 
with the severity of CAD, and increased levels of NT-proB-
NP independently predicted the presence of more complex 
coronary lesions [27]. Sahin Arslan and colleagues reported 
that plasma levels of BNP were higher in stable CAD patients 
with coronary artery stenosis of more than 50% compared to 
those with less stenosis; also, the level of increase in plasma 
BNP concentration was positively correlated with the extent 
of lesion on coronary angiography [16]. Some other studies 
have also found that the NT-proBNP level has been correlat-
ed with the severity of coronary artery stenosis and Gensini 
score and suggested that the NT-proBNP level can be used as 
a predictor of angiographic results [10, 20, 28].
Despite the significant correlation between NT-proBNP lev-
els and Gensini scores in our patients, the NT-proBNP levels 
were not significantly different in patients with SVD, 2VD 
and 3VD (P = 0.257). Inconsistent with our results, some 
studies have reported that NT-proBNP levels were positively 
correlated with the number of coronary vessels involved [10, 
16]. However, individuals enrolled in those studies were pa-
tients with stable CAD. We also did not find any correlation 
between LAD involvement and NT-proBNP level; but in a 
study on patients with stable CAD [16] and another study 
on patients with UA and NSTEMI [29], patients with LAD 
involvement had higher NT-proBNP levels. Moreover, the 
results of our study showed that there was a direct correlation 
between NT-proBNP and troponin I levels (correlation coef-
ficient = 0.779) in patients with ACS.
In addition to previous reports on higher NT-proBNP lev-
els in patients with heart failure, we found that NT-proBNP 
levels had a negative correlation with EF in patients with 
ACS, too (correlation coefficient = -0.55; P = 0.001). Some 
researchers have reported same results in patients with 
NSTEMI [27] and stable CAD [20].
Besides, while dyslipidemia and high blood sugar are risk fac-
tors of CAD; neither NT-proBNP levels nor Gensini scores 
were correlated with plasma levels of HDL, LDL, TG, cho-
lesterol and blood sugar. Additionally, in contrast to Gensini 
score, smoker patients had higher NT-proBNP levels (P = 
0.047).
To conclude, serum levels of NT-proBNP can be used as an 
important biomarker for risk stratification of patients with 
ACS by predicting the CAD severity, Gensini score and tro-
ponin I levels. Further studies with higher numbers of pa-
tients are necessary to confirm the results of the current study.
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